Characteristics of Cytokine Response in Patients With Temporomandibular Disorders Treated With Occlusal Splint Therapy
Temporomandibular Joint Disorders
About this trial
This is an interventional basic science trial for Temporomandibular Joint Disorders focused on measuring prospective study, interventional study
Eligibility Criteria
Inclusion Criteria: signed informed consent TMP pain screening scores ≥ 3 patients with natural teeth diagnoses: myalgia, arthralgia, headache attributed to TMP and painful disc displacement (with and without reduction) according to axis I diagnostic criteria for temporomandibular disorders (DK/TMP) Exclusion Criteria: degenerative joint disease and subluxation of the temporomandibular joint (TMJ) head trauma orofacial pain not associated with temporomandibular disorders patients with fixed or removable prostheses patients who are currently undergoing orthodontic therapy and/or using occlusal splints patients who used anti-inflammatory drugs and muscle relaxants 48 hours before data collection, and patients who use drugs with an impact on the immune system (such as antiproliferative immunosuppressants, corticosteroids and other immunosuppressants, antirheumatic drugs, DMARDs, anti-lymphocyte monoclonal antibodies and other immunomodulating drugs , antidepressants, antiepileptics) periodontitis pregnancy
Sites / Locations
- Helath Center Osijek-Baranja countyRecruiting
Arms of the Study
Arm 1
Experimental
TMD pain group
The arm includes patients with TMP pain screening scores ≥ 3 and with diagnosis of myalgia, arthralgia, headache attributed to TMP and painful disc displacement (with and without reduction) according to Axis I diagnostic criteria for temporomandibular disorders (DK/TMP). Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance.